

**Unaudited Financial Results for the Quarter ended 30th June, 2008**

(Rs.in Millions)

Particulars	Stand alone			Consolidated		
	First Quarter Ended		Year Ended	First Quarter Ended		Year ended
	30.06.2008	30.06.2007	31.03.2008	30.06.2008	31.03.2007	31.03.2008
	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)
Sales(including excise duty)	6,744	5,087	23,511	7,068	5,611	25,523
Less: Excise Duty	271	287	1,164	271	288	1,164
Net Sales	6,473	4,800	22,347	6,797	5,323	24,359
Other Operating Income	58	33	582	35	33	106
Other Income	7	7	118	15	8	144
<b>Total Income</b>	<b>6,538</b>	<b>4,840</b>	<b>23,047</b>	<b>6,847</b>	<b>5,364</b>	<b>24,609</b>
Expenditure						
a. (Increase)/ Decrease in Stock	2	(345)	(347)	(100)	(440)	(712)
b. Material Consumed	3,793	3,240	13,755	3,572	3,037	12,612
c. Purchase of traded goods	16	45	118	217	330	1,615
d. Staff Cost	437	337	1,487	574	442	1,930
e. Depreciation/ Amortisation	195	174	746	270	234	1,004
f. Other Expenditure	1,027	984	4,160	1,425	1,259	5,504
<b>Total expenditure</b>	<b>5,470</b>	<b>4,435</b>	<b>19,919</b>	<b>5,958</b>	<b>4,862</b>	<b>21,953</b>
<b>Profit Before, Interest &amp; Tax</b>	<b>1,068</b>	<b>405</b>	<b>3,128</b>	<b>889</b>	<b>502</b>	<b>2,656</b>
Interest (net)	71	44	161	132	106	432
Foreign Exchange (Gain)/ Loss	560	(289)	(481)	537	(294)	(693)
<b>Profit from Ordinary Activities before tax</b>	<b>437</b>	<b>650</b>	<b>3,448</b>	<b>220</b>	<b>690</b>	<b>2,917</b>
Provision for Taxation						
a. Current Tax (MAT)	49	76	484	65	81	479
b. MAT Credit Entitlement	(41)	(4)	-	(41)	(4)	-
c. Deferred Tax	10	8	52	10	(8)	52
d. Fringe Benefit Tax (net of recovery)	1	1	5	1	1	5
e. Tax adjustments of previous years	20	-	-	20	-	-
Total Tax	39	65	541	55	70	536
<b>Profit before Minority Interest</b>	<b>398</b>	<b>585</b>	<b>2,907</b>	<b>165</b>	<b>620</b>	<b>2,381</b>
Minority Interest				1	3	(3)
<b>Net Profit for the period</b>	<b>398</b>	<b>585</b>	<b>2,907</b>	<b>164</b>	<b>617</b>	<b>2,384</b>
Paid-up Equity Share Capital	268.82	266.74	268.82	268.82	266.74	268.82
(Face value Rs. 5 per share)						
Reserves excluding Revaluation Reserves			11,937			10,971
Basic Earnings per share before & after Extraordinary items (Rs.) (not annualised)	7.42	10.97	54.21	3.06	11.57	44.46
Diluted Earnings per share before & after Extraordinary items (Rs.) (not annualised)	5.90	8.66	43.07	2.43	9.13	35.33
Public Shareholding						
a. Number of Shares	24,049,036	26,636,405	24,049,036	24,049,036	26,636,405	24,049,036
b. Percentage of Shareholding	44.73	44.31	44.73	44.73	44.31	44.73

**Notes:**

- The above unaudited financial results were reviewed by the Audit Committee and have been approved by the Board at its meeting held on 30.07.2008. The quarterly stand alone results are subject to Limited Review by Auditors of the Company.
- The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.
- The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement', AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all subsidiaries and 50:50 Joint Ventures.
- The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- Investor complaints pending at the beginning of the quarter: Nil, received: 45, resolved:45 and lying unresolved at the end of the quarter Nil.
- Sales for the quarter include exports of Rs.4386.8 Millions (Rs.2772.0 Millions).
- Other Operating Income represents sale of dossier.
- Foreign Exchange (Gain)/Loss represents exchange differences arising during the period on all foreign currency transactions. This includes Loss due to restatement of Foreign Currency Convertible Bonds (net of Deposits) Rs.566.2 Millions (Gain of Rs.408.5 Millions).
- Premium on redemption of USD 255.5 Million zero coupon Foreign Currency Convertible Bonds is contingent in nature, the outcome of which is dependant on uncertain future events.
- During the quarter, the Company has formed a new step-down subsidiary viz., Aurobindo Pharma (Portugal) Unipessoal Limitada.
- Figures for the previous periods have been rearranged/regrouped wherever necessary to make it comparable.

For and on behalf of the Board  
Sd/-

K.Nithyananda Reddy  
Managing Director

Place: Hyderabad  
Date : 30.07.2008